TORONTO, April 26, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions a ...

Key PointsThe Amplify Alternative Harvest ETF has 30 holdings in cannabis stocks, providing investors with diversification within the industry.Cannabis stocks have been making headlines due to the April 1, 2024, legalization of cannabis in Germany.The U.S. Department of Health and Human Services (HHS) has recommended the DEA consider reclassifying cannabis to a Schedule III drug down from a Schedule I drug, which currently carries a maximum prison sentence of 20 years to life.5 stocks we like better than Am ...

Even with a relatively small allocation, meme stocks can be game-changers for portfolio returns. Multibagger returns within a few quarters are not uncommon in the world of meme stocks. This column focuses on meme stocks to buy in April for returns in the range of 50% to 100% before the end of 2024.There were two primary catalysts for the meme stocks discussed. First, these stocks represent ideas with industry or company-specific tailwinds that will drive growth and value creation.Further, the season for mem ...

Summary of Cronos Group Inc. Conference Call Company Overview - **Company**: Cronos Group Inc. (NASDAQ:CRON) - **Event**: Roth MKM 36th Annual ROTH Conference - **Date**: March 18, 2024 - **Participants**: Mike Gorenstein (CEO, Chairman), Bill Kirk (ROTH MKM) Industry Insights Canadian Cannabis Market Dynamics - The Canadian cannabis market has experienced a multi-year period of oversupply, but the supply-demand dynamic is shifting. While overall supply exceeds demand, much of the excess product is unsuitable for sale due to expiration or low potency [2][3] - There is a notable reduction in the availability of high-quality products, leading to opportunities for price increases rather than price compression in the flour segment [3][4] - Regulatory changes, including enforcement of tax compliance by the CRA (Canadian IRS), have contributed to a decrease in unsustainable supply in the market [4] Market Fragmentation and Brand Strategy - Large players in the Canadian market have struggled to maintain market share despite M&A activities, often leading to brand cannibalization and lack of differentiation [8][9] - Cronos Group has focused on building a single strong brand, Spinach, and has avoided acquiring other brands that do not align with their strategy [10][11] Product Differentiation - Spinach SOURZ and Chocolate Fusions are highlighted as examples of differentiated products that resonate well with consumers due to unique flavor profiles and textures [12][15] - The company emphasizes the importance of product differentiation in the cannabis industry, as consumers prioritize product quality over lifestyle branding [13] Financial Performance and Cost Management - In 2023, Cronos Group achieved $30 million in cost savings, with expectations of an additional $5 to $10 million in 2024 [16][17] - The company has maintained a strong cash position with $860 million available, allowing for flexibility in capital use and potential M&A opportunities [29][30] Regulatory Environment and Future Outlook U.S. Market Potential - There is optimism regarding potential regulatory changes in the U.S., particularly the implementation of Schedule 3, which could occur before the upcoming election [26][27] - Cronos Group is preparing for various regulatory scenarios and aims to maintain a strong product portfolio regardless of changes [29][31] International Opportunities - The company is exploring international markets, including Germany, where recent regulatory changes may allow for better marketing and distribution of cannabis products [35][40] - Cronos Group has cultivation operations in Israel and is also exporting products from Canada to meet demand in various markets [42] Future Market Trends - The illicit cannabis market in the U.S. is compared to Canada, with similar dynamics observed in states with relaxed enforcement [32] - The company anticipates that successful legalization in Germany could influence other European countries to follow suit, potentially opening new markets [46] Conclusion - Cronos Group is strategically positioned to capitalize on evolving market dynamics in the cannabis industry, focusing on product differentiation, cost management, and regulatory preparedness to enhance its competitive advantage in both domestic and international markets [48][49]

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the 36th Annual Roth Conference on Monday, March 18, 2024, at 8:30AM PT. A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cronos is an innovative global cannabin ...

Cannabis stocks have gone through multiple phases of high volatility in the last five years. Traders might have benefited from this volatility, but the sector has disappointed long-term investors. However, it finally seems that cannabis stocks might be positioned for a sustained rally.There are multiple reasons for this view. First, several cannabis companies have managed to stem the cash burn, and fundamentals look better. Further, there seems to be optimism on the regulatory front. Germany recently legali ...

3 Marijuana Stocks For Your March WatchlistMarijuana stock investors are starting to see the upside of 2024. Since the start of January 1st, there has been much speculation and anticipation for the cannabis sector. Knowing that this year is a presidential election also means better trading. Not to mention the ongoing fight to establish federal reform for the US cannabis industry. So with both parties needing votes, we may see potential campaign promises for legal cannabis.Nevertheless, even if nothing comes ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ Form 10-K __________________ | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------| | For the transition period from Commission File No. \n__________________________ CRONOS GROUP (Exact name of Registrant as sp ...

Financial Data and Key Metrics Changes - The company reported consolidated net revenue of $23.9 million for Q4 2023, a 9% increase from the prior year, with constant currency revenue increasing by 11% to $24.5 million [48] - For the full year 2023, net revenue increased by 1% year-over-year to $87.2 million, with constant currency revenue up 6% to $91.7 million [60] - Gross profit for Q4 was $1.9 million, equating to an 8% gross margin, representing a $0.7 million improvement from the prior year [48] - Operating cash flow improved by $46 million to negative $43 million for the year [60] Business Line Data and Key Metrics Changes - The Spinach brand closed 2023 as the number 1 ranked flower brand in Canada with a 6.9% market share in Q4, up from 4th ranked in 2022 [4] - Spinach edibles accounted for 16.2% of the market's retail sales in Q4, maintaining its position as the market leader in edibles [5] - The Lord Jones brand launched new products, including Chocolate Fusions, which are expected to expand the chocolate segment in the cannabis market [35] Market Data and Key Metrics Changes - In the U.S. market, there is increased momentum to reclassify cannabis, which could significantly improve the operational landscape for cannabis companies [7] - The Australian market reached approximately $200 million in retail sales in 2023, indicating significant growth potential [33] - The German market is expected to experience growth following legislative changes that allow for better marketing of medical cannabis [32][44] Company Strategy and Development Direction - The company aims to capitalize on opportunities in 2024, having achieved $30 million in operating expense savings in 2023, exceeding the target of $20 million to $25 million [2] - The strategy includes focusing on brand innovation and maintaining an asset-light model to enhance operational efficiency [7] - The exit from the Winnipeg facility is anticipated to drive additional cost savings in 2024 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in recovering from Q4 performance and building upon the success of the first nine months of 2023 [11][20] - The company is well-positioned to take advantage of new market growth opportunities due to its strong balance sheet and operational improvements [10][49] - Management highlighted the resilience of the workforce in Israel despite geopolitical challenges, indicating a commitment to maintaining product quality [3][14] Other Important Information - The company ended the quarter with approximately $862 million in cash and short-term investments, up by about $22 million from Q3 [49] - The company has a 5.9% stake in PharmaCann and a 10% stake in Vitura, contributing to its diversified portfolio [10] - The company anticipates generating approximately $40 million to $50 million in interest income in 2024 [38] Q&A Session Summary Question: What were the main drivers of the lower gross margin in Q4? - The lower gross margin was predominantly driven by increased competitive activity in Israel due to the war and some inventory write-downs [58] Question: What are the growth prospects in Australia and Germany? - Australia is becoming more crowded, but there are barriers to entry that may sustain growth. In Germany, recent legislative changes allow for better marketing of medical cannabis, which is expected to unlock growth [54][66] Question: How does the company view competition in the market? - The company noted competition in Israel driven by the war, but emphasized that their facility was not directly impacted and they continue to produce high-quality products [14]

Ended 2023 with approximately $862 million in cash and short-term investments Commenced sales to Australian partner Launched award-winning Lord Jones® brand in Canada Consolidated net revenue increased 9% in Q4 2023 compared to Q4 2022; on a constant currency basis consolidated net revenue increased 11% in Q4 2023 compared to Q4 2022 Net revenue in Canada increased 20% in Q4 2023 compared to Q4 2022; on a constant currency basis net revenue in Canada increased 21% in Q4 2023 compared to Q4 2022 TORONTO, Feb ...